Cellular Biomedicine Group Completes Enrollment in Phase I Clinical Trial for Knee Osteoarthritis
PALO ALTO, Calif., July 22, 2013 /PRNewswire/ -- Cellular Biomedicine Group (OTCQB:CBMG) today announced that it has completed the enrollment required for its Phase I trial to evaluate the safety and preliminary efficacy of the medical technology haMPC (Human Adipose-derived Mesenchymal Progenitor Cells) therapy for Knee Osteoarthritis (KOA).
"We are pleased that our patient enrollment is on schedule with our projected time to complete the Phase I clinical trial for Knee Osteoarthritis," said Dr. Cheng Xiang (Chase) Dai, VP and GM of Autologous Products Business Unit.
The Phase I open label clinical research trial for KOA, registered with the U.S. National Institutes of Health (NIH) under number NCT01809769 (click here to view), tests the safety and efficacy of intra-articular injections of autologous (patient's own) haMPC in order to reduce inflammation and regenerate damaged joint tissues. This trial is conducted at Shanghai Renji Hospital, one of the largest teaching hospitals in China. To date the trial has had no Severe Adverse Effect (SAE) reported.
Knee Osteoarthritis in China
There are approximately 57 million people in China suffering from knee osteoarthritis (source: International Journal of Rheumatic Diseases, 2011) As drug-based methods of management are ineffective, many patients with this disability will degenerate to the point of requiring artificial joint replacement surgery every year.
About Cellular Biomedicine Group
Cellular Biomedicine Group, Inc. develops proprietary cell therapies for the treatment of certain degenerative diseases and cancers. Our developmental stem cell, progenitor cell, and immune cell projects are the result of research and development by scientists and doctors from China and the United States. Our flagship GMP facility, consisting of eight independent cell production lines, is designed, certified and managed according to U.S. standards. To learn more about CBMG, please visit: www.cellbiomedgroup.com
Statements in this press release relating to plans, strategies, trends, specific activities or investments, and other statements that are not descriptions of historical facts may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include, but are not limited to, risk factors inherent in doing business. Forward-looking statements may be identified by terms such as "may," "will," "expects," "plans," "intends," "estimates," "potential," or "continue," or similar terms or the negative of these terms. Although CBMG believes the expectations reflected in the forward-looking statements are reasonable, they cannot guarantee that future results, levels of activity, performance or achievements will be obtained. CBMG does not have any obligation to update these forward-looking statements other than as required by law.
SOURCE Cellular Biomedicine Group
More by this Source
Cellular Biomedicine Group Announces Adjournment of Its Annual Shareholder Meeting
Nov 09, 2013, 05:55 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.